Continuing Clozapine Despite Neutropenia

1996 ◽  
Vol 168 (2) ◽  
pp. 217-220 ◽  
Author(s):  
Michael L. Wesson ◽  
David M. Finnegan ◽  
Peter I. Clark

BackgroundA 40-year-old chronic schizophrenic patient whose psychosis and associated violent behaviour resolved on clozapine, required chemotherapy for a testicular teratoma with pulmonary metastases. His treatment was initially delayed due to refusal to consent.TreatmentThe patient finally agreed to orchidectomy and cytotoxic therapy, and following agreement by the CPMS, clozapine continued to be dispensed despite neutropenia and ‘red alert’ status on full blood count.DiscussionThis is the only patient to continue clozapine despite ‘red alert’ status, and as such is an exceptional case, but may open the way for such patients in the future.

1959 ◽  
Vol 105 (441) ◽  
pp. 1112-1118
Author(s):  
G. A. Dransfield ◽  
M. W. Browne

Recent work, such as that of Moore and Martin (1957), has shown that reserpine is of value in the treatment of the chronic schizophrenic patient. Attention has however been drawn to the incidence of side-effects in this form of treatment. These side-effects have limited the application of the drug and have also led to the search for a related substance, of similar clinical effect but without the troublesome toxic effects. This present trial is of a substance, deserpidine (Harmonyl, Abbott Laboratories), which it was thought would fulfil these requirements. The isolation of this alkaloid was first reported in 1955 by Stoll and Hofman, and it has subsequently been identified as 11-desmethoxy-reserpine (Harrisson, 1955) which can be represented thus:


Psychiatry ◽  
1984 ◽  
Vol 47 (4) ◽  
pp. 324-332 ◽  
Author(s):  
Michael A. Selzer ◽  
Monica Carsky ◽  
Bruce Gilbert ◽  
William Weiss ◽  
Matthew Klein ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document